Focus on Colorectal Cancer ResearchNova Publishers, 2005 - 327 páginas In Western countries, cancer of the large intestine and rectum (colorectal cancer) is the second most common type of cancer and the second leading cause of cancer death (after lung cancer). The incidence of colorectal cancer begins to rise at age 40 and peaks between ages 60 and 75. Cancer of the large intestine (colon cancer) is more common in women; rectal cancer is more common in men. About 5 percent of the people with colon or rectal cancer have more than one cancer of the colorectum at the same time. People with a family history of colon cancer have a higher risk of developing the cancer themselves. A family history of familial polyposis or a similar disease also increases the risk of colon cancer. People with ulcerative colitis or Crohn's disease have a higher risk of developing cancer. The risk is related to the person's age when the condition developed and the length of time the person has had the condition. Diet plays some role in the risk of colon cancer, but exactly how it affects risk is unknown. Throughout the world, people at highest risk tend to live in cities and eat a diet typical of affluent Westerners. Such a diet is low in fibre and high in animal protein, fats, and refined carbohydrates such as sugar. Risk seems to be reduced by a diet high in calcium, vitamin D, and vegetables such as brussel sprouts, cabbage, and broccoli. |
Índice
1 | |
Protective Effect of Physical Activity on the Occurrence of Colorectal Cancer | 25 |
Role of Phytochemicals in Colon Carcinogenesis | 41 |
Colorectal Cancer and the Growth HormoneInsulinLike Growth FactorI Axis | 65 |
Antitumour Activity of Yogurt | 97 |
COX2 Prostaglandins and Colon Cancer | 123 |
Early Colorectal Cancer New Diagnostic Methods and Colonoscopic Therapeutic Techniques | 143 |
Treatment of Advanced Colorectal Cancer Current Status and Future Perspectives | 171 |
Laparoscopic Surgery for Colon and Rectal Cancer | 209 |
Development and Application of a New Trial Design for the Analysis of an Immune Modulator GCSF GranulocyteColony Stimulating Factor for Im... | 241 |
Hereditary Colorectal Cancer | 287 |
323 | |
Términos y frases comunes
adenomas advanced colorectal cancer analysis angiogenesis apoptosis assessment Cancer Res cancer risk carcinogenesis cell lines chemopreventive chemotherapy clinical trials colectomy colon cancer colon cancer cells colon carcinogenesis Colon Rectum colonoscopy colorectal cancer colorectal carcinoma colorectal lesions curcumin cytokines decrease detection disease drugs effect endoscopic endpoint enzymes expression familial adenomatous polyposis fluorouracil G-CSF Gastroenterology gene genetic hereditary hMLH1 HNPCC IGF-I immune response increased induced inhibition inhibitor insulin-like growth factor irinotecan kinase laparoscopic laparotomy large intestine levels malignant mechanisms metastasis mice microsatellite instability mismatch repair modulation molecular mucosal mutations NSAID Nutr oxaliplatin pathway patients Perdigón physical activity pneumoperitoneum polyps port site metastasis postoperative prevention proliferation prostaglandin protein randomized rats receptor rectal cancer recurrence regulation reported resection role sepsis signalling sporadic sulindac Surg Endosc surgery surgical survival syndrome therapy tissue treatment tumor cells vitro vivo yogurt
Pasajes populares
Página 21 - Incidence and functional consequences of hMLHl promoter hypermethylation in colorectal carcinoma.
Página 21 - Bos. JL. Fearon, ER. Hamilton. SR. Verlaan-de Vries, M.. van Boom, JH. van der Eb, AJ. and Vogelstein, B. Prevalence of ras gene mutations in human colorectal cancers. Nature (Lond.), 327: 293-297.
Página 20 - Vogelstein, B., Fearon, ER, Hamilton, SR, Kern, SE, Preisinger, AC, Leppert, M., Nakamura, Y., White, R., Smits, AMM, and Bos, JL, Genetic alterations during colorectal-tumor development, N.